IPI Speaks with Mr Anil Busimi, VP, Strategy & Marketing of Terumo Medical Care Solutions (TMCS)
on the Recent Changes in the CDMO Industry and what the Market is Looking for Now.
Q: Terumo is a core player in the healthcare market. Can you tell our readers a brief history of the company, how you started and your growth so far?
A: Terumo Corporation is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for over 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
Terumo has three companies encompassing global businesses.
• Cardiac and Vascular Company
• Medical Care Solutions Company
• Blood and Cell Technologies Company
As part of Terumo Medical Care Solutions, the Pharmaceutical Solutions Division develops patient-oriented parenteral delivery solutions for therapeutic performance and safety.
We offer pharmaceutical and medical device manufacturers around the world comprehensive product design and development services through our decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialisation to optimise critical aspects of parenteral drug delivery.
Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies, including pre-fillable syringes, CDMO services for all parenteral applications.
Q: Terumo Corporation has recently renamed the “General Hospital Company” to its new name “Medical Care Solutions Company”. What prompted this move, and how will this impact your standing in the industry?
A: The new Brand Medical Care Solutions Company was launched as part of our continued growth and Terumo’s 5-Year Growth Strategy (GS26).
The landscape of healthcare today is facing a paradigm shift. The point of care is not limited to in-hospital treatments but has expanded to in-home care. There are increased needs for more personalised treatment, as well as improving hospital management efficiency and safety. The brand promise of Terumo Medical Care Solutions, “Quality time for better care,” embodies the values and the wide scope of solutions the Medical Care Solutions Company provides today and carries the promise to provide this quality time for better care to everyone involved in healthcare.
